References
- Ridker, et al.. Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein. N Engl J Med. 2008;359:2195–207.
- De Lorgeril, et al.. Cholesterol Lowering cardiovascular Diseases and the Rosuvastatin-JUPITER Controversy. A Critical Reappraisal. Arch Intern Med. 2010;170(12):1032–1036.
- Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7–22.
- Koenig W, Sund M, Frohlich M, et al.. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsberg Cohort Study, 1984 to 1992. Circulation. 1999;99:237–242.
- Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105:1135–1143.
- Pasceri V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation. 2000;102: 2165–2168.
- Downs JR, Clearfield M, Weis S, et al.. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA. 1998;279:1615–22.
- Ridker PM, Rifai N, Clearfield M, et al.. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. N Engl J Med. 2001;344:1959–1965.
- Pearson TA, Mensah GA, Alexander RW, et al.. Markers of inflammation and cardiovascular disease. Application to clinical and public health practice: a statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511.
- Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial. Circulation2003;108:2292–7.
- Crestor Summary of Product Characteristics. Internet [cited 27 Sept 2010]. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo = verFichaWordPdf&codigo = 70243&formato = pdf&formulario = FICHAS
- Montori V, Permanyer-Miralda G, Ferreira-González I, Busse JW, Pacheco-Huergo V, Bryant D. Validity of composite end points in clinical trials. BMJ. Mar. 2005; 330: 594–596.
- Bassler D, Briel M, Montori VM, et al.. Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA. 2010;303(12):1180–1187.
- Mueller PS, et al.. Ethical Issues in Stopping Randomized Controlled Trials Early Because of Apparent Benefit. Ann Intern Med. 2007;146:878–881.
- Kaul S, et al.. By Jove! What is a Clinician to Make of JUPITER. Arch Intern Med2010;170(12):1073–1075.
- Vaccarino V, et al.. JUPITER. A Few Words of Caution. Circ Cardiovasc Qual Outcomes. 2009;2:286–88.
- Zacho J, Tybjærg-Hansen A, Jensen JS, et al.. Genetically elevated C-reactive protein and ischemic vascular disease. N Engl J Med. 2008;359:1897–908.
- Schunkert H, et al.. Elevated C-Reactive Protein in Atherosclerosis — Chicken or Egg? N Engl J Med. 2008;359:1953–1955.
- Ridker, et al.. Relation of baseline High-sensitivity C-reactive proteín level to cardiovascular Outcomes with Rosuvastatin in the Justification for use of statins in prevention: an interventional Trial Evaluating Rosuvastatin (JUPITER). Am J Cardiol. 2010;106:204–209.
- Sever P. The Ango-Scandinavian Cardiac Outcomes Trial (ASCOT): Testing C-reactive protein at baseline and on-treatment as an independent predictor of cardiovascular outcomes. American Heart Association 2010 Scientific Sessions, November 17, 2010; Chicago, IL, Late-breaking clinical trials IV.
- http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021366s016StatR.pdf
- Chan, et al.. Letter to the editor. N Engl J Med. 2009;360(10):1039.
- Tunstall-Pedoe H, et al.. Contribution of trends in survival and coronary-event rates to changes in coronary heart disease mortality: 10-year results from 37 WHO MONICA Project populations: monitoring trends and determinants in cardiovascular disease. Lancet1999;353(9164);1547–1557.
- http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021366s016StatR.pdf. 24. Visitado 27–9–2010 </othinfo>
- Kjekshus J, Apetrei E, Barrios V, et al.. Rosuvastatin in older patients with Systolic heart failure. N Engl J Med. 2007; 357:2248–61. Available from the Internet [accessed 27 Sept 2010]: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/021366s016StatR.pdf
- Gissi-HF investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISS-HF trial): a randomised, double blind, placebo-controlled trial. Lancet. 2008; 372:1231–39.
- Fellstrom BC, Jardine AG, et al.. ‘Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis.’ N. Engl. J. Med. 360(14): 1395–1407.
- Search Study Collaborative Group. Study of the effectiveness of additional reductions in cholesterol and homocysteine (SEARCH): characteristics of a randomized trial among 12064 myocardial infarction survivors. Am Heart J. 2007;154(5):815–823.
- Association of Crestor (rosuvastatin) with muscle related adverse events—AstraZeneca Canada Inc. Available from the Internet [accessed 11 Mar 2005]: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/crestor2_hpc_e.html
- FDA Public Health Advisory on Crestor (rosuvastatin). Available from the Internet [Accessed June 2004]:http://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm166321.htm
- FDA Public Health Advisory for Crestor. Available from the Internet [accessed June 2005]: http://www.fda.gov/Drugs/DrugSafety/PublicHealthAdvisories/ucm051756.htm
- Sattar N, et al.. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010;375:735–42.
- Ridker P. The JUPITER Trial. Results, controversies, and implications for Prevention. Cir Cardiovasc Qual Outcomes. 2009;2:279–285.
- Ray KK, et al.. Statins and All-Cause Mortality in High-Risk Primary Prevention. Arch Intern Med. 2010;170(12):1024–1031.
- Therapeutics Letter dated March–April 2010. http://ti.ubc.ca/PDF/77.pdf